Evidence map›Paper›PMID 37418052›Full record

SynthesisIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2023

Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.

Saurabh Chandan, Smit Deliwala, Babu P Mohan, Daryl Ramai, Banreet Dhindsa, Jay Bapaye, Lena L Kassab, Ojasvini Choudhry Chandan, Antonio Facciorusso, Douglas G Adler

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Saurabh ChandanDivision of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, NE, USA.
Smit DeliwalaDivision of Digestive Diseases, Emory University, Atlanta, GA, USA.
Babu P MohanGastroenterology and Hepatology, University of Utah Health School of Medicine, Salt Lake City, UT, USA.
Daryl RamaiGastroenterology and Hepatology, University of Utah Health School of Medicine, Salt Lake City, UT, USA.
Banreet DhindsaDepartment of Gastroenterology and Hepatology, University of Nebraska Medical Center|, Omaha, NE, USA.
Jay BapayeDepartment of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.
Lena L KassabDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Ojasvini Choudhry ChandanDepartment of Pediatric Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, USA.
Antonio FacciorussoGastroenterology Unit, Department of Surgical and Medical Sciences, University of Foggia, Foggia, Italy.
Douglas G AdlerCenter for Advanced Therapeutic Endoscopy, Centura Health, Denver, CO, USA. Douglasadler@centura.org.
University of Nebraska Medical Center · USUniversity of Utah · USCreighton University · USEmory University · USMayo Clinic in Arizona · USRochester General Hospital · USUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton-pump inhibitors (PPIs) are the mainstay of treatment in erosive esophagitis (EE). An alternative to PPIs in EE is Vonoprazan, a potassium competitive acid blocker. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing vonoprazan to lansoprazole.

methodsMultiple databases searched through November 2022. Meta-analysis was performed to assess endoscopic healing at two, four and eight weeks, including for patients with severe EE (Los Angeles C/D). Serious adverse events (SAE) leading to drug discontinuation were assessed. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.

resultsFour RCTs with 2208 patients were included in the final analysis. Vonoprazan 20 mg once-daily was compared to lansoprazole 30 mg once-daily dosing. Among all patients, at two and eight weeks post-treatment, vonoprazan resulted in significantly higher rates of endoscopic healing as compared to lansoprazole, risk ratios (RR) 1.1, p<0.001 and RR 1.04, p=0.03. The same effect was not observed at four weeks, RR 1.03 (CI 0.99-1.06, I

conclusionBased on limited number of published non-inferiority RCTs, our analysis demonstrates that among patients with EE, vonoprazan 20 mg once-daily dosing achieves comparable and in those with severe EE, higher endoscopic healing rates as compared to lansoprazole 30 mg once-daily dosing. Both drugs have a comparable safety profile.

Indexed as

EsophagitisPeptic UlcerHumansLansoprazoleProton Pump InhibitorsPyrrolesRandomized Controlled Trials as TopicSulfonamides1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLansoprazoleProton Pump InhibitorsPyrrolesSulfonamidesErosive esophagitisLansoprazolePPIVonoprazan

Identifiers

PMID37418052
OpenAlexW4383481748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.